While the effects of the pandemic on businesses are starting to ease, some companies made great leaps forward over the last couple of years. One of these is hVivo (formerly Open Orphan), the Cathal Friel-backed contract research organisation. Despite the high price/earnings rating for the shares, they look to be heading in the right direction.
Open Orphan is a specialist contract research organisation which, with the acquisition of hVivo at the end of 2019 (and the subsequent name change from Open Orphan to hVivo), has developed into a leading tester of vaccines for infectious and respiratory diseases as well as of therapeutics using human challenge clinical trials.
The group provides end-to-end early clinical development services to a number of big pharma companies, which currently include four of the top 10 global biopharma businesses by scale.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
